Pimasertib

Pimasertib (AS703026) is a highly selective, ATP non-competitive allosteric orally available MEK1/2 inhibitor[1][2].

Product Specifications

CAS Number

[1236699-92-5]

Product Name Alternative

AS703026; MSC1936369B

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

MEK

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/AS703026.html

Purity

99.60

Solubility

DMSO : ≥ 100 mg/mL

Smiles

FC1=C(C=CC(I)=C1)NC2=CN=CC=C2C(NC[C@@H](CO)O)=O

Molecular Formula

C15H15FIN3O3

Molecular Weight

431.20

Precautions

H302, H315, H319, H335

References & Citations

[1]Kim K, et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol, 2010, 149 (4), 537-549.|[2]Yoon J, et al. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res, 2011, 71 (2), 445-453.|[3]Park SJ, et al. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells. Am J Med Sci. 2013 Dec;346 (6) :494-8.